Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels

Table 1 Breakdown of Treatments by Systemic Therapies and Site of Radiotherapy

Metastatic Status	Therapy		# ExaminationPairs		Sites of Radiotherapy
Metastatic Status	Therapy		No RT^f	With RT^f	Sites of Radiotherapy
mHSPC^a (N = 27)	LHRH agonists		12	4	pelvic bone cervical/dorsal spine other nodes other sites
	TAB^c (antiandrogens + LHRH agonists)		6	1	prostate and pelvic bone
	TAB + CHT^d		4
mCRPC^b (N = 23)	Abiraterone or Enzalutamide		2	2	pelvic bone cervical/dorsal/lumbosacral spine
	Abiraterone or Enzalutamide + LHRH agonists		7	2	dorsal spine+ limbs pelvic bone, retroperitoneal + other nodes
	Abiraterone or Enzalutamide + LHRH agonists + CHT		2
	CHT		4
	Other	Radiometabolic (Radium 223)	1
		Enzalutamide vs Placebo + ADT^e	2
		LHRH Agonists + Immunotherapy (antitelomerase vaccine)	1

^a mHSPC metastatic hormone-sensitive prostate cancer
^b mCRPC metastatic castration resistant prostate cancer
^c TAB triple androgen blockade (Cyproterone acetate, Bicalutamide, or Flutamide; Leuprolide acetate, Buserelin, Goserelin, or Triptorelin; or Degarelix)
^d CHT chemotherapy (Docetaxel, Cabazitaxel)
^e ADT androgen deprivation therapy
^f RT radiotherapy

ISSN: 1470-7330